litlas
Log inCreate account

John A. Thompson

Active 1975–2026

Also published as
John A Thompson · John A.Thompson
208
Papers
51,122
Citations
107
h-index
195
i10-index

Citations

Citations per year for John A. Thompson1956: 1 citations1975: 1 citations1976: 1 citations1977: 3 citations1978: 1 citations1979: 1 citations1981: 2 citations1982: 1 citations1983: 2 citations1984: 2 citations1985: 3 citations1986: 5 citations1987: 6 citations1988: 26 citations1989: 26 citations1990: 46 citations1991: 45 citations1992: 36 citations1993: 26 citations1994: 21 citations1995: 29 citations1996: 40 citations1997: 71 citations1998: 94 citations1999: 116 citations2000: 167 citations2001: 212 citations2002: 252 citations2003: 303 citations2004: 299 citations2005: 313 citations2006: 292 citations2007: 314 citations2008: 318 citations2009: 359 citations2010: 394 citations2011: 400 citations2012: 329 citations2013: 397 citations2014: 297 citations2015: 317 citations2016: 258 citations2017: 291 citations2018: 354 citations2019: 1,194 citations2020: 1,506 citations2021: 1,473 citations2022: 1,287 citations2023: 1,034 citations2024: 1,694 citations2025: 698 citations2026: 26 citations1957–1974: no citations, so these years are not shown1980: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 6,279 citing papers, 32.4% of this breakdownChina: 1,657 citing papers, 8.6% of this breakdownGermany: 1,124 citing papers, 5.8% of this breakdownUnited Kingdom: 1,023 citing papers, 5.3% of this breakdownItaly: 986 citing papers, 5.1% of this breakdownFrance: 824 citing papers, 4.2% of this breakdownAustralia: 650 citing papers, 3.4% of this breakdownJapan: 637 citing papers, 3.3% of this breakdownCanada: 589 citing papers, 3% of this breakdownNetherlands: 533 citing papers, 2.7% of this breakdownSpain: 489 citing papers, 2.5% of this breakdownSwitzerland: 477 citing papers, 2.5% of this breakdown
0%32.4%Other 21.2%

Institutions

Fields

  • Medicine64.7%
  • Biochemistry, Genetics and Molecular Biology15.9%
  • Immunology and Microbiology11.3%
  • Computer Science2.4%
  • Engineering1.1%
  • Neuroscience1%
  • Other3.6%

Topics

  • Cancer Immunotherapy and Biomarkers10.2%
  • Immunotherapy and Immune Responses5.7%
  • CAR-T cell therapy research5.4%
  • Cutaneous Melanoma Detection and Management3.3%
  • Immune Cell Function and Interaction3.3%
  • Melanoma and MAPK Pathways2.3%
  • Other69.8%

Coauthors

All papers

Open in search
  1. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

    Authors: Bryan J. Schneider, Jarushka Naidoo, Bianca D. Santomasso, Christina Lacchetti, Sherry Adkins, Milan Anadkat, Michael B. Atkins, Kelly J. Brassil, Jeffrey M. Caterino, Ian Chau, Marianne J. Davies, Marc S. Ernstoff, Leslie Fecher, Monalisa Ghosh, Ishmael Jaiyesimi, Jennifer S. Mammen, Aung Naing, Loretta J. Nastoupil, Tanyanika Phillips, Laura D. Porter, Cristina A. Reichner, Carole Seigel, Jung-Min Song, Alexander Spira, Maria Suarez-Almazor, Umang Swami, John A. Thompson, Praveen Vikas, Yinghong Wang, Jeffrey S. Weber, Pauline Funchain, Kathryn Bollin - Journal of Clinical Oncology 2021 cited by 1,964

  2. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

    Authors: Filipe Martins, Sofiya Latifyan, Gerasimos P. Sykiotis, Faïza Lamine, Michel H. Maillard, Montserrat Fraga, Keyvan Shabafrouz, Camillo Ribi, Anne Cairoli, Yan Guex‐Crosier, Thierry Küntzer, Olivier Michielin, Solange Peters, George Coukos, François Spertini, John A. Thompson, Michel Obéid - Nature Reviews Clinical Oncology 2019 cited by 2,242

  3. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

    Authors: Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider, Michael B. Atkins, Kelly Brassil, Jeffrey M. Caterino, Ian Chau, Marc S. Ernstoff, Jennifer M. Gardner, Pamela Ginex, Sigrun Hallmeyer, Jennifer Holter Chakrabarty, Natasha B. Leighl, Jennifer S. Mammen, David F. McDermott, Aung Naing, Loretta J. Nastoupil, Tanyanika Phillips, Laura Porter, Igor Puzanov, Cristina Reichner, Bianca Santomasso, Carole Seigel, Alexander I. Spira, María E. Suarez‐Almazor, Yinghong Wang, Jeffrey S. Weber, Jedd D. Wolchok, John A. Thompson - Journal of Clinical Oncology 2018 cited by 3,697

  4. Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology

    Authors: John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, Amaka Achufusi, Philippe Armand, Meghan Berkenstock, Shailender Bhatia, Lihua E. Budde, Saurin Chokshi, Marianne Davies, Amro Elshoury, Yaron Gesthalter, Aparna Hegde, Michael D. Jain, Benjamin H. Kaffenberger, Melissa G. Lechner, Tianhong Li, Alissa Marr, Suzanne McGettigan, Jordan P. McPherson, Theresa Medina, Nisha Mohindra, Anthony J. Olszanski, Olalekan O. Oluwole, Sandip Pravin Patel, Pradnya D. Patil, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Yinghong Wang, Vlad G. Zaha, Megan Lyons, Mary A. Dwyer, Lisa Hang - Journal of the National Comprehensive Cancer Network 2022 cited by 418

  5. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

    Authors: Bianca D. Santomasso, Loretta J. Nastoupil, Sherry Adkins, Christina Lacchetti, Bryan J. Schneider, Milan Anadkat, Michael B. Atkins, Kelly J. Brassil, Jeffrey M. Caterino, Ian Chau, Marianne J. Davies, Marc S. Ernstoff, Leslie Fecher, Pauline Funchain, Ishmael Jaiyesimi, Jennifer S. Mammen, Jarushka Naidoo, Aung Naing, Tanyanika Phillips, Laura D. Porter, Cristina A. Reichner, Carole Seigel, Jung-Min Song, Alexander Spira, Maria Suarez-Almazor, Umang Swami, John A. Thompson, Praveen Vikas, Yinghong Wang, Jeffrey S. Weber, Kathryn Bollin, Monalisa Ghosh - Journal of Clinical Oncology 2021 cited by 376

  6. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

    Authors: Paul Nghiem, Shailender Bhatia, Evan J. Lipson, Ragini R. Kudchadkar, Natalie Miller, Lakshmanan Annamalai, Sneha Berry, Elliot Chartash, Adil Daud, Steven P. Fling, Philip Friedlander, Harriet M. Kluger, Holbrook E. Kohrt, Lisa Lundgren, Kim Margolin, Alan Mitchell, Thomas Olencki, Drew M. Pardoll, Sunil Reddy, Erica Shantha, William H. Sharfman, Elad Sharon, Lynn Shemanski, Michi M. Shinohara, Joel Sunshine, Janis M. Taube, John A. Thompson, Steven M. Townson, Jennifer H. Yearley, Suzanne L. Topalian, Martin A. Cheever - New England Journal of Medicine 2016 cited by 1,243

  7. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

    Authors: John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano J. Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew J. Frigault, Benjamin H. Kaffenberger, Matthew A. Lunning, Suzanne McGettigan, Jordan P. McPherson, Nisha Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan O. Oluwole, Sandip Pravin Patel, Nathan A. Pennell, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Yinghong Wang, Ryan Weight, Alyse Johnson-Chilla, Griselda Zuccarino-Catania, Anita M. Engh - Journal of the National Comprehensive Cancer Network 2020 cited by 486

  8. Guidelines of care for the management of primary cutaneous melanoma

    Authors: Susan M. Swetter, Hensin Tsao, Christopher K. Bichakjian, Clara Curiel‐Lewandrowski, David E. Elder, Jeffrey E. Gershenwald, Valerie Guild, Jane M. Grant‐Kels, Allan C. Halpern, Timothy M. Johnson, Arthur J. Sober, John A. Thompson, Oliver J. Wisco, Samantha Wyatt, Shasa Hu, Toyin Lamina - Journal of the American Academy of Dermatology 2018 cited by 708

  9. Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function

    Authors: Joshua Veatch, Sylvia M. Lee, Carolyn Shasha, Naina Singhi, Julia Szeto, Ata S. Moshiri, Teresa S. Kim, Kimberly S. Smythe, Paul Kong, Matthew Fitzgibbon, Brenda L. Jesernig, Shailender Bhatia, Scott S. Tykodi, Evan Hall, David R. Byrd, John A. Thompson, Venu G. Pillarisetty, Thomas Duhen, A. McGarry Houghton, Evan W. Newell, Raphaël Gottardo, Stanley R. Riddell - Cancer Cell 2022 cited by 144

  10. Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

    Authors: John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano J. Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew J. Frigault, Brianna Hoffner, Christopher Hoimes, Mario E. Lacouture, Frederick L. Locke, Matthew A. Lunning, Nisha Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan O. Oluwole, Sandip Pravin Patel, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Momen M. Wahidi, Yinghong Wang, Alyse Johnson-Chilla, Jillian L. Scavone - Journal of the National Comprehensive Cancer Network 2019 cited by 560

  11. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

    Authors: Robert J. Motzer, Bernard Escudier, Stéphane Oudard, Thomas E. Hutson, Camillo Porta, Sergio Bracarda, Viktor Grünwald, John A. Thompson, Robert A. Figlin, Norbert Hollaender, Gladys Urbanowitz, William J. Berg, Andrea Kay, David Lebwohl, Alain Ravaud - The Lancet 2008 cited by 3,012

  12. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021

    Authors: Susan M. Swetter, John A. Thompson, Mark R. Albertini, Christopher A. Barker, Joel Baumgartner, Genevieve M. Boland, Bartosz Chmielowski, Dominick J. DiMaio, Alison B. Durham, Ryan C. Fields, Martin D. Fleming, Anjela Galan, Brian Gastman, Kenneth F. Grossmann, Samantha Guild, Ashley M. Holder, Douglas B. Johnson, Richard W. Joseph, Giorgos C. Karakousis, Kari Kendra, Julie R. Lange, Ryan M. Lanning, Kim Margolin, Anthony J. Olszanski, Patrick A. Ott, Merrick I. Ross, April K.S. Salama, Rohit Sharma, Joseph J. Skitzki, Jeffrey A. Sosman, Evan Wuthrick, Nicole R. McMillian, Anita M. Engh - Journal of the National Comprehensive Cancer Network 2021 cited by 337

  13. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study

    Authors: Fangwen Zou, David M. Faleck, Anusha Shirwaikar Thomas, Jessica Harris, Deepika Satish, Xuemei Wang, Aline Charabaty, Marc S. Ernstoff, Isabella C. Glitza Oliva, Stephen B. Hanauer, Jennifer L. McQuade, Michel Obéid, Amishi Y. Shah, David M. Richards, Elad Sharon, Jedd D. Wolchok, John A. Thompson, Yinghong Wang - Journal for ImmunoTherapy of Cancer 2021 cited by 117

  14. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    Authors: Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Роберто Пили, Georg A. Bjarnason, Xavier García del Muro, Jeffrey A. Sosman, E Solska, George Wilding, John A. Thompson, Sindy T. Kim, Isan Chen, Xin Huang, Robert A. Figlin - Journal of Clinical Oncology 2009 cited by 2,189

  15. Age-Specific Incidence of Melanoma in the United States

    Authors: Kelly G. Paulson, Deepti Gupta, Teresa S. Kim, Joshua Veatch, David R. Byrd, Shailender Bhatia, Katherine Y. Wojcik, Aude G. Chapuis, John A. Thompson, Margaret M. Madeleine, Jennifer M. Gardner - JAMA Dermatology 2019 cited by 224

  16. First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation.

    Authors: Ecaterina E. Dumbrava, Melissa L. Johnson, Anthony W. Tolcher, Geoffrey I. Shapiro, John A. Thompson, Anthony B. El-Khoueiry, Andrae Lavon Vandross, Shivaani Kummar, Aparna R. Parikh, Pamela N. Münster, Erika Daly, Laura de Leon, Megan Khaddar, Kimberley LeDuke, Kimberly A. Robell, Lisa Iacono Sheehan, Meagen St. Louis, Amy E. Wiebesiek, Leila Alland, Alison M. Schram - Journal of Clinical Oncology 2022 cited by 81

  17. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy

    Authors: John B.A.G. Haanen, Marc S. Ernstoff, Yinghong Wang, Alexander M. Menzies, Igor Puzanov, Petros Grivas, James Larkin, Solange Peters, John A. Thompson, Michel Obéid - Journal for ImmunoTherapy of Cancer 2020 cited by 167

  18. Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics

    Authors: Kelly G. Paulson, Song Youn Park, Natalie Vandeven, Kristina Lachance, Hannah Thomas, Aude G. Chapuis, Kelly L. Harms, John A. Thompson, Shailender Bhatia, Andreas Stang, Paul Nghiem - Journal of the American Academy of Dermatology 2017 cited by 504

  19. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy

    Authors: John B.A.G. Haanen, Marc S. Ernstoff, Yinghong Wang, Alexander M. Menzies, Igor Puzanov, Petros Grivas, James Larkin, Solange Peters, John A. Thompson, Michel Obéid - Annals of Oncology 2020 cited by 231

  20. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary

    Authors: Julie R. Brahmer, Christina Lacchetti, John A. Thompson - Journal of Oncology Practice 2018 cited by 373

  21. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

    Authors: Brigitte Dréno, John F Thompson, B. Mark Smithers, Mario Santinami, Thomas Jouary, Ralf Gutzmer, E. Levchenko, Piotr Rutkowski, Jean-Jacques Grob, S.I. Korovin, Kamil Drucis, Florent Grange, L. Machet, Peter Hersey, Ivana Krajsová, Alessandro Testori, Robert M. Conry, B. Guillot, Wim H.J. Kruit, Lev Demidov, John A. Thompson, Igor Bondarenko, Jarosław Jaroszek, Susana Puig, Gabriela Cinat, Axel Hauschild, Jelle J. Goeman, Hans C. van Houwelingen, Fernando Ulloa-Montoya, Andrea Callegaro, Benjamin Dizier, Bart Spiessens, Muriel Debois, Vincent Brichard, Jamila Louahed, Patrick Therasse, C. Debruyne, John M. Kirkwood - The Lancet Oncology 2018 cited by 198

  22. A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors

    Authors: Jeffrey S. Miller, Chihiro Morishima, Douglas G. McNeel, Manish R. Patel, Holbrook E. Kohrt, John A. Thompson, Paul M. Sondel, Heather A. Wakelee, Mary L. Disis, Judith C. Kaiser, Martin A. Cheever, Howard Streicher, S P Creekmore, Thomas A. Waldmann, Kevin C. Conlon - Clinical Cancer Research 2017 cited by 195

  23. Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1

    Authors: Naomi Hunder, Herschel Wallen, Jianhong Cao, Deborah W. Hendricks, J. Zachary Reilly, Rebecca M. Rodmyre, Achim A. Jungbluth, Sacha Gnjatic, John A. Thompson, Cassian Yee - New England Journal of Medicine 2008 cited by 905

  24. Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System

    Authors: Charles M. Balch, Seng‐Jaw Soong, Jeffrey E. Gershenwald, John F. Thompson, Douglas S. Reintgen, Natale Cascinelli, Marshall M. Urist, Kelly M. McMasters, Merrick I. Ross, John M. Kirkwood, Michael B. Atkins, John A. Thompson, Daniel G. Coit, David R. Byrd, Renée A. Desmond, Yuting Zhang, Ping‐Yu Liu, Gary H. Lyman, Aberto Morabito - Journal of Clinical Oncology 2001 cited by 2,401